Patent ID: 7890267
Filing Date: 2011-02-15
Classification: C12Q,G01N,Y10T

Abstract:
1. A method for diagnosing prostate cancer or predicting prostate cancer-therapy outcome in a subject, said method comprising the step of measuring the expression of two or more markers in a tumor sample from the subject wherein the two or more markers are selected from the group consisting of: (1) the histone H3 protein methylated at lysine residue 27 (H3metK27); (2) the histone H2A protein ubiquinated at lysine residue 119 (H2AubiK119) (3) BMI1and H2AubiK 119; and (4) EZH2and H3metK27, wherein high expression of the two or more markers in the tumor sample indicates an aggressive form of cancer and a poor prognosis.